GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Windlas Biotech Ltd (NSE:WINDLAS) » Definitions » Capex-to-Operating-Income

Windlas Biotech (NSE:WINDLAS) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Windlas Biotech Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Windlas Biotech's Capital Expenditure for the three months ended in Mar. 2025 was ₹0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was ₹172.13 Mil.

Hence, Windlas Biotech's Capex-to-Operating-Income for the three months ended in Mar. 2025 was 0.00.


Windlas Biotech Capex-to-Operating-Income Historical Data

The historical data trend for Windlas Biotech's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windlas Biotech Capex-to-Operating-Income Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Capex-to-Operating-Income
Get a 7-Day Free Trial 0.13 0.37 1.48 0.58 0.79

Windlas Biotech Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Windlas Biotech's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Windlas Biotech's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Windlas Biotech's Capex-to-Operating-Income falls into.


;
;

Windlas Biotech Capex-to-Operating-Income Calculation

Windlas Biotech's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-521.94) / 661.22
=0.79

Windlas Biotech's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 172.13
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Windlas Biotech  (NSE:WINDLAS) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Windlas Biotech Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Windlas Biotech's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Windlas Biotech Business Description

Traded in Other Exchanges
Address
Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.

Windlas Biotech Headlines

No Headlines